31 May 2023 | 15:00-15:45 CEST
About this webinar
The use of highly effective treatments with strong anti-inflammatory activity from the early stages of multiple sclerosis (MS) has unveiled the concept of progression independent of relapse activity (PIRA). Witnessed in both progressive and relapsing forms of MS, it refers to an accumulation of disability independent of relapse-associated worsening (RAW), and related to inflammatory mechanisms. But what do we really know about the phenomenon, and how it fits into the complex jigsaw of MS care?
In this webinar, our panel of experts will discuss the growing evidence base, the latest research on and around PIRA, and how they expect it to affect best clinical practice.
- Moderator: Alan Thompson, Dean of the Faculty of Brain Sciences at University College London; editor of the Multiple Sclerosis Journal
- Speaker: Carmen Tur, Neurologist, Multiple Sclerosis Centre of Catalonia (CEMCAT)
- Speaker: Cristina Granziera, ECTRIMS Executive Committee Member and Senior Consultant Neurologist at University Hospital of Basel